Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
VRX [NYSE]
Valeant Pharmaceuticals International, Inc.
Index- P/E- EPS (ttm)-2.60 Insider Own2.30% Shs Outstand333.66M Perf Week10.91%
Market Cap44.45B Forward P/E- EPS next Y- Insider Trans7.03% Shs Float330.28M Perf Month1.34%
Income-866.10M PEG- EPS next Q- Inst Own95.80% Short Float1.10% Perf Quarter-3.33%
Sales5.77B P/S7.70 EPS this Y-610.50% Inst Trans-3.08% Short Ratio1.55 Perf Half Y18.64%
Book/sh15.30 P/B8.71 EPS next Y- ROA-3.70% Target Price52.38 Perf Year77.69%
Cash/sh1.80 P/C74.05 EPS next 5Y15.24% ROE-17.90% 52W Range71.99 - 153.10 Perf YTD13.48%
Dividend- P/FCF51.88 EPS past 5Y-33.00% ROI-0.10% 52W High-12.98% Beta0.93
Dividend %- Quick Ratio1.20 Sales past 5Y50.10% Gross Margin67.00% 52W Low85.07% ATR6.07
Employees17200 Current Ratio1.50 Sales Q/Q124.30% Oper. Margin4.60% RSI (14)54.22 Volatility4.12% 4.99%
OptionableYes Debt/Eq3.39 EPS Q/Q227.60% Profit Margin-15.00% Rel Volume2.21 Prev Close135.41
ShortableYes LT Debt/Eq3.35 EarningsMay 05 Payout- Avg Volume2.33M Price133.23
Recom3.00 SMA205.62% SMA50-1.88% SMA20015.32% Volume5,003,000 Change-1.61%
28-Feb-14Reiterated UBS Buy $141 → $170
28-Feb-14Reiterated RBC Capital Mkts Outperform $151 → $158
27-Feb-14Reiterated Aegis Capital Buy $160 → $180
08-Jan-14Reiterated UBS Buy $125 → $141
08-Jan-14Reiterated Ladenburg Thalmann Buy $123 → $155
08-Jan-14Reiterated FBR Capital Outperform $130 → $153
03-Dec-13Reiterated UBS Buy $115 → $125
01-Nov-13Reiterated Ladenburg Thalmann Buy $127 → $123
30-Oct-13Initiated FBR Capital Outperform $130
07-Oct-13Reiterated CRT Capital Buy $110 → $130
08-Aug-13Reiterated UBS Buy $96 → $115
07-Aug-13Reiterated Aegis Capital Buy $135 → $140
02-Jul-13Reiterated RBC Capital Mkts Outperform $76 → $100
10-Jun-13Upgrade CRT Capital Hold → Buy $100
29-May-13Reiterated Ladenburg Thalmann Buy $84 → $124
29-May-13Reiterated Deutsche Bank Buy $82 → $103
03-May-13Reiterated Deutsche Bank Buy $80 → $82
04-Apr-13Reiterated UBS Buy $83 → $81
04-Apr-13Reiterated RBC Capital Mkts Outperform $80 → $76
21-Mar-13Reiterated Deutsche Bank Buy $77 → $83
24-Apr-14 05:11AM  [video] Well See A Lot More Pharmaceutical Deals: Chouhan at Bloomberg
23-Apr-14 07:36PM  CNBC transcript: Warren Buffett on Coke pay plan at CNBC
06:28PM  Can Endo's CEO Do An Encore Of His Playbook At Valeant? Guru Funds Think So. at Seeking Alpha
06:15PM  [video] Shareholder activism your friend: Cramer at CNBC
03:19PM  [video] CEOs terrified of activists: Buffett at CNBC
03:01PM  In Allergan Bid, a Question of Insider Trading at New York Times
02:31PM  Can Allergan Find an Alternative To Valeant? at Motley Fool
02:15PM  Ackmans Pershing Square Subsidiaries Hint at Future Moves at New York Times
01:34PM  [video] Bill Ackman's 'quiet' trade at CNBC
01:32PM  The future of pharma lies in research, not cost-cutting at Financial Times
01:32PM  [video] Hedge fund & big pharma pair up at CNBC
12:41PM  [video] How Ackman built Allergan stake at CNBC
12:39PM  Ackman's Allergan play: Not insider trading, not a problem for private equity at Fortune
12:09PM  My Herbalife short is looking much better: Ackman at CNBC
12:02PM  Carl Icahn defends Ackman, slams Lipton at CNBC
12:00PM  [video] Icahn on Lipton, Ackman at CNBC
11:50AM  [video] Bill Ackman Goes Corporate Raider Route Backing Valeant in Allergan Bid at TheStreet
11:18AM  [video] Ackman on Herbalife short at CNBC
11:00AM  [video] Pharma deal frenzy at CNBC
10:25AM  Pharma Drama: Pfizer Fails to Woo AstraZeneca; Valeant Pursues Allergan at Wall St. Cheat Sheet
10:13AM  Morning six-pack: What we're reading Wednesday at CNBC
09:52AM  Why Bill Ackman and Valeant Are Bidding for Allergan at Motley Fool
09:40AM  I did not front-run Allergan stock, Ackman says at CNBC
09:19AM  [video] Carl Icahn's take on Ackman & Valeant at CNBC
09:17AM  [video] Cramer: Can't lose if you're Ackman at CNBC
09:15AM  Allergan, Inc.: Another Billion-Dollar Buyout Target at Motley Fool
08:56AM  'Poison pill' won't disrupt Allergan deal: Ackman at CNBC
08:52AM  Why Valeant International Inc. Is Acquiring Botox and Juvederm Maker Allergan at Motley Fool
08:45AM  [video] Cramer: It wasn't front running at CNBC
08:22AM  How Will Allergan (AGN) Stock Be Affected By Poison Pill Stance Against Valeant (VRX), Ackman? at TheStreet
08:16AM  'Poison pill' won't disrupt Allergan deal: Ackman at CNBC
08:01AM  Valeant Pharmaceuticals Announces Nominations For Board Of Directors CNW Group
08:00AM  Valeant Pharmaceuticals Announces Nominations For Board Of Directors PR Newswire
07:58AM  Ackman: Didn't violate insider-trading rules over Allergan at MarketWatch
07:48AM  [video] Ackman: Partnership with Valeant is not front running at CNBC
07:41AM  [video] Ackman: Allergan clear fit for Valeant at CNBC
07:40AM  'Poison pill' won't disrupt Allergan deal: Ackman at CNBC
07:37AM  [video] Valeant CEO: Deal will get done despite 'poison pill' at CNBC
07:33AM  [video] Valeant CEO: Allergan has a great set of assets at CNBC
07:32AM  [video] Ackman: Valeant fit into Pershing investing mold at CNBC
06:31AM  What burst of M&A activity says about the market at CNBC
06:02AM  Wednesday's Artery-Clogging Fast-Food Earnings Reports, and Potential Botox Merger at Motley Fool
05:53AM  Allergan upgraded to Overweight from Neutral at JPMorgan theflyonthewall.com
03:48AM  Allergan adopts poison pill in face of Valeant bid at MarketWatch
01:54AM  Valeant Pharmaceuticals International (VRX) Soars: Stock Up 7.5% Zacks
22-Apr-14 10:24PM  ALLERGAN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Allergan, Inc. PR Newswire +7.46%
10:14PM  Asia shares mixed after HSBC China flash PMI; Japan's Seibu rallies at CNBC
09:00PM  Asia shares gain ahead of HSBC China flash PMI at CNBC
08:41PM  Valeant, Ackman make $45.6B Allergan bid AP
08:21PM  Asia shares gain ahead of HSBC China flash PMI at CNBC
07:27PM  Jim Cramer's 'Mad Money' Recap: Opportunities Are Still Out There at TheStreet
06:59PM  Asia shares seen higher; focus on HSBC China flash PMI at CNBC
06:40PM  Wall Street's bull market starts to show its age at CNBC
06:16PM  Hostile Allergan bid: Cramer hopes Ackman whiffs at CNBC
06:16PM  Hostile Allergan bid: Cramer hopes Ackman & Valeant whiff at CNBC
06:15PM  [video] Icahn: We see things boards don't at CNBC
06:11PM  Valeant's Bid For Allergan Boosts Ethical Drug Stocks at Investor's Business Daily
05:50PM  Drug M&A Revives In Drive To Expand, But Also To Focus Investor's Business Daily
05:30PM  [video] ValueAct passes Valeant torch to Pershing at CNBC
05:16PM  Why GW Pharmaceuticals, Revance Therapeutics, and Allergan Are Today's 3 Best Stocks at Motley Fool
05:15PM  Stocks Rise In Higher Volume; Gilead Up After Hours at Investor's Business Daily
05:00PM  [video] Positive earnings strengthen market at CNBC
05:00PM  [video] Merger mania sweeps Wall Street at CNBC
04:59PM  Unmentioned But Potent Leading Indicators at Forbes
04:53PM  Ackman: No Laws Broken in Allergan Buy at Fox Business
04:33PM  [audio] Newscast: Stocks notch another win at MarketWatch
04:29PM  S&P 500, Nasdaq Rise For Sixth Day As Volume Picks Up at Investor's Business Daily
04:24PM  Earnings and big pharma deals drive stocks up Hot Stock Minute
04:17PM  Stocks Flirt With All-Time Highs on Earnings, Deals News at TheStreet
04:16PM  S&P 500 seals first six-day win streak since September at CNBC
04:16PM  Why Valeant Pharmaceuticals (VRX) Stock Is Up Today at TheStreet
04:06PM  Can Valeant Work Its Magic On Allergan, Or Is Pearson Biting Off More Than He Can Chew? at Forbes
04:03PM  5 reasons to care about Ackman's Botox bet at CNNMoney.com
03:38PM  How Valeant Can Raise Its Bid for Botox Maker at New York Times
03:33PM  [$$] Valeant, Ackman Bid for Allergan Should Pay Off at Barrons.com
03:30PM  Investors anticipate higher Allergan bids amid Valeant's hostile takeover at MarketWatch
03:15PM  Bill Ackman Outs Valeant CEO Mike Pearson As A Billionaire at Forbes
03:14PM  Stocks up thanks to Netflix, big pharma at CNNMoney.com
03:12PM  Allergan soars on Valeant bid; Netflix jumps on results at MarketWatch
03:04PM  Why Allergan Inc. Shares Skyrocketed at Motley Fool
02:58PM  Valeant says won't pay whatever price necessary for Allergan, Reuters says at theflyonthewall.com
02:50PM  After a rough year Bill Ackman is the comeback kid at CNBC
02:44PM  Valeant Pharmaceuticals International -- Moody's revises Valeant's outlook to developing at Moody's
02:43PM  [$$] Valeant, Ackman Bid for Allergan Should Pay Off at Barrons.com
02:18PM  Stocks rise on M&A activity and earnings; Nasdaq up 1.1 percent at CNBC
02:18PM  Botox. It's more than just a wrinkle buster at CNBC
01:59PM  Stocks rise on earnings; Nasdaq up 1% and Dow jumps 100-plus points at CNBC
01:53PM  [video] Power Rundown: Activist, Aereo & airlines at CNBC
01:44PM  [video] New age of shareholder activism at CNBC
01:37PM  2 Biotech Stocks to Trade (or Not) at TheStreet
01:36PM  Pershing Square and Valeant's Allergan Deal a Watershed for Activism at TheStreet
01:36PM  Behind Bill Ackman's deal for Botox maker Allergan at Fortune
01:32PM  Nasdaq, Health Care Lead Stock Market Higher at Investor's Business Daily
01:27PM  Allergan Bid Charts New Territory in Takeovers at New York Times
01:26PM  Market Hustle: Stocks Gain on Earnings, Deals News at TheStreet
01:21PM  Will Idera Pharmaceuticals (IDRA) Stock Sustain Today's Rally? at TheStreet
01:15PM  How one trader made $250,0000 overnight on FURX at CNBC
01:12PM  Stocks up thanks to Netflix, big pharma at CNNMoney.com
01:10PM  [video] How to play big pharma at CNBC
01:03PM  Ackman puts a new twist on activism with Allergan bid Breakout
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Its pharmaceutical products include Solodyn, an oral antibiotic that treats red and pus-filled pimples, as well as Ziana, Acanya, and Atralin; Wellbutrin XL, a formulation used for the treatment of major depressive disorder in adults; Xenazine for the treatment of chorea; Zovirax Cream for herpes labialis; Zovirax ointment for initial genital herpes; The Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; and Prolensa, a non-steroidal anti-inflammatory ophthalmic solution. The company also provides OTC products, such as PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus, a sterile that is used to lubricate and rewet soft contact lenses; Ocuvite, a lutein eye vitamin and mineral supplement; Artelac, an eye drops to treat dry eyes; and CeraVe products for skin. In addition, it offers device products, including SofLens daily disposable contact lenses; Restylane, an injectable implant dermal fillers; PureVision, a contact lens; Dysport, an injection neurotoxin; ophthalmic surgical products, such as Akreos and Crystalens; surgical equipment comprising the VICTUS femtosecond laser and the Stellaris PC, a vitreoretinal and cataract surgery system; and medical device systems for aesthetic applications. Further, it provides generic products comprising Retin-A Micro, a tretinoin gel; tobramycin and dexamethasone ophthalmic suspensions for steroid responsive inflammatory ocular conditions; and latanoprost to treat glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Provencio Norma AnnDirectorApr 01Sale132.185,000660,886137,495Apr 02 04:55 PM
Kornwasser LaizerEVP, Company Group ChairmanMar 21Buy134.972,481334,85953,582Mar 25 01:06 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.Mar 17Option Exercise6.455,00032,25028,999Mar 19 04:33 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.Mar 17Sale141.725,000708,60023,999Mar 19 04:33 PM
Weldon RyanEVP, Company Group ChairmanFeb 11Option Exercise0.0011,0000103,823Feb 12 04:43 PM
Stolz Brian M.EVP, Administration & CHCOFeb 11Option Exercise0.0014,700069,783Feb 12 04:08 PM
Schiller Howard BradleyEVP, CFOFeb 11Option Exercise0.0090,0000312,704Feb 12 03:51 PM
Kornwasser LaizerEVP, Company Group ChairmanFeb 11Option Exercise0.0045,000073,390Feb 12 03:34 PM
Provencio Norma AnnDirectorFeb 03Sale136.235,000681,158147,206Feb 04 06:15 PM
Weldon RyanEVP, Company Group ChairmanJan 24Option Exercise0.0019,0000101,539Jan 28 05:09 PM
Mirovsky PavelPresident of Valeant EuropeJan 24Option Exercise0.0010,000010,000Jan 28 05:00 PM
Kornwasser LaizerEVP, Company Group ChairmanJan 24Buy132.152,536335,12828,390Jan 28 04:51 PM
Stolz Brian M.EVP, Administration and CHCOJan 20Option Exercise0.0045,000077,939Jan 22 04:55 PM